Levodropropizine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Levodropropizine is a peripherally-acting antitussive agent.

Generic Name
Levodropropizine
DrugBank Accession Number
DB12472
Background

Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 236.315
Monoisotopic: 236.152477892
Chemical Formula
C13H20N2O2
Synonyms
  • levodropropizina
  • Levodropropizine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofCoughing••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
LEVOPRONT SYRUP 60 mg/10 mlSyrup60 mg/10mlOralEMERGING PHARMA (S) PTE LTD1999-03-24Not applicableSingapore flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DROPOLEV ŞURUP ,150 MLLevodropropizine (30 mg/5ml) + Chlorpheniramine maleate (2 mg/5ml)SyrupOralBERKO İLAÇ VE KİMYA SAN. A.Ş.2014-09-09Not applicableTurkey flag
PULMOTUS 30 MG+ 2 MG/5 ML ŞURUP, 150 MLLevodropropizine (30 mg/5mL) + Chlorpheniramine maleate (2 mg/5mL)SyrupOralBERAT BERAN İLAÇ SAN. VE TİC. LTD. ŞTİ.2019-09-10Not applicableTurkey flag

Categories

ATC Codes
R05DB27 — Levodropropizine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / 1,3-aminoalcohols / Trialkylamines / Secondary alcohols / 1,2-diols / 1,2-aminoalcohols / Azacyclic compounds
show 3 more
Substituents
1,2-aminoalcohol / 1,2-diol / 1,3-aminoalcohol / Alcohol / Amine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Dialkylarylamine
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-arylpiperazine, secondary alcohol, N-alkylpiperazine (CHEBI:82722)
Affected organisms
Not Available

Chemical Identifiers

UNII
3O31P6T4G3
CAS number
99291-25-5
InChI Key
PTVWPYVOOKLBCG-ZDUSSCGKSA-N
InChI
InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1
IUPAC Name
(2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol
SMILES
[H][C@@](O)(CO)CN1CCN(CC1)C1=CC=CC=C1

References

General References
  1. AIFA Product Information: Salvituss (levodropropizine) for oral use [Link]
PubChem Compound
65859
PubChem Substance
347828710
ChemSpider
59270
RxNav
52014
ChEBI
82722
ChEMBL
CHEMBL1288810
ZINC
ZINC000019594545
Wikipedia
Levodropropizine

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral0.6 g
SolutionOral60 mg
SyrupOral30 mg/5ml
SyrupOral
SyrupOral600 mg
SyrupOral6 mg/mL
Solution / dropsOral60 MG/ML
SyrupOral
TabletOral60 mg
SyrupOral60 mg/5ml
SolutionOral0.06 g
SyrupOral60 mg/10ml
SyrupOral0.6 g
SyrupOral60000000 mg
Solution / dropsOral
SolutionOral
SyrupOral0.6 mg
SolutionOral60.000 mg
SyrupOral0.600 g
TabletOral60.000 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility97.1 mg/mLALOGPS
logP0.63ALOGPS
logP0.61Chemaxon
logS-0.39ALOGPS
pKa (Strongest Acidic)14Chemaxon
pKa (Strongest Basic)7.65Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area46.94 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity68.79 m3·mol-1Chemaxon
Polarizability26.77 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-02di-6940000000-2c6f504ceae818e3ed7e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-3411eeea47aa1faaee17
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0290000000-23aac6510a50f0f89473
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01tl-4930000000-3cac032ee3deea5c1893
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014r-0190000000-4136122f26318c05670e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0n93-3920000000-3ede8eb0d08697e769fe
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9700000000-1a50ebc2d9b0bc1958a5
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-164.8452545
predicted
DarkChem Lite v0.1.0
[M-H]-151.35706
predicted
DeepCCS 1.0 (2019)
[M+H]+164.9686545
predicted
DarkChem Lite v0.1.0
[M+H]+153.75261
predicted
DeepCCS 1.0 (2019)
[M+Na]+159.66515
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:31 / Updated at May 27, 2021 02:58